The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
Open accessAbstract
Purpose: Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP). Patients and Methods: Patients with previously untreated histologically or cytologically proven locally advanced or metastatic carcinoma of the pancreas with a performance status ≤ 2 were recruited. Patients were randomly assigned to GEM or GEM-CAP. The primary outcome measure was survival. Meta-analysis of published studies was also conducted. Results: Between May 2002 and January 2005, 533 patients were randomly assigned to GEM (n = 266) and GEM-CAP (n = 267) arms. GEM-CAP significantly improved objective response rate (19.1% v 12.4%; P = .034) and progression-free survival (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .004) and was associated with a trend toward improved OS (HR, 0.86; 95% CI, 0.72 to 1.02; P = .08) compared with GEM alone. This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077). Moreover, the meta-analysis of two additional studies involving 935 patients showed a significant survival benefit in favor of GEM-CAP (HR, 0.86; 95% CI, 0.75 to 0.98; P = .02) with no intertrial heterogeneity. Conclusion: On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Self-citationMiller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
Glimelius, B., Hoffman, K., Sjödén, P.-O., Jacobsson, G., Sellström, H., Enander, L.-K., Linné, T., & Svensson, C. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010676 · Cited by 797
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.-L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 650
Self-citationHerrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schüller, J., Saletti, P., Bauer, J., Figer, A., Pestalozzi, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0886 · Cited by 595
Self-citationMeta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., & Ghaneh, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2551 · Cited by 442
Self-citationCassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf089 · Cited by 425
Analysing and Presenting Results
Macaskill, P., Gatsonis, C., Deeks, J. J., Harbord, R., & Takwoingi, Y. (2010) · Bristol Research (University of Bristol) · Cited by 337
Kindler, H. L., Niedzwiecki, D., Hollis, D., Oraefo, E., Schrag, D., Hurwitz, H., McLeod, H. L., Mulcahy, M. F., Schilsky, R. L., & Goldberg, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4508 · Cited by 235
for the European Study Group of Pancreatic Cancer, Neoptolemos, J. P., Stocken, D. D., Tudur Smith, C., Bassi, C., Ghaneh, P., Owen, E., Moore, M., Padbury, R., Doi, R., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604838 · Cited by 204
Self-citationPhase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer
Cartwright, T. H., Cohn, A. L., Varkey, J. A., Chen, Y.-M., Szatrowski, T. P., Cox, J. V., & Schulz, J. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.160 · Cited by 201
Scheithauer, W., Schüll, B., Ulrich-Pur, H., Schmid, K., Raderer, M., Haider, K., Kwasny, W., Depisch, D., Schneeweiss, B., Lang, F., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg029 · Cited by 187
Self-citationPhilip, P. A., Benedetti, J., Fenoglio-Preiser, C., Zalupski, M., Lenz, H., O'Reilly, E., Wong, R., Atkins, J., Abruzzese, J., & Blanke, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.lba4509 · Cited by 186
Maisey, N. R., Chau, I., Cunningham, D., Norman, A. R., Seymour, M., Hickish, T., Iveson, T. J., O'Brien, M. E. R., Tebbutt, N. C., Harrington, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.029 · Cited by 136
Self-citationPelzer, U., Kubica, K., Stieler, J., Schwaner, I., Heil, G., Görner, M., Mölle, M., Hilbig, A., Dörken, B., Riess, H. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4508 · Cited by 127
Hess, V., Salzberg, M. O., Borner, M., Morant, R., Roth, A. D., Ludwig, C., & Herrmann, R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.029 · Cited by 95
Self-citationChau, I., Cunningham, D., Russell, C., Norman, A. R., Kurzawinski, T. R., Harper, P., Harrison, P. M., Middleton, G., Daniels, F. H., Hickish, T., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603058 · Cited by 81
Self-citationBoeck, S. H., Hoehler, T., Seipelt, G., Mahlberg, R., Wein, A., Hochhaus, A., Böck, H.-P., Schmid, B., Kettner, E., Stauch, M. B., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm467 · Cited by 78
Stathopoulos, G. P., Syrigos, K. N., Polyzos, A., Fountzilas, G., Rigatos, S. K., Ziras, N., Potamiannou, A., Tsiakopoulos, I., Androulakis, N. E. M., Aravantinos, G., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh065 · Cited by 58
Schilsky, R. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.582 · Cited by 52
Analysis of messy longitudinal data from a randomized clinical trial
Qian, W., Parmar, M., Sambrook, R., Fayers, P. M., Girling, D. J., & Stephens, R. J. (2000) · Statistics in Medicine · Cited by 36
Cited by
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Self-citation
Metadata
- Authors
- Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., Falk, S., Crellin, A., Adab, F., Thompson, J., Leonard, P., Ostrowski, J., Eatock, M., Scheithauer, W., Herrmann, R., & Neoptolemos, J. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-11-20
- Volume
- 27
- Issue
- 33
- Pages
- 5513-5518
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2083452953
- Cited by
- 823
- References
- 31
- FWCI
- 31.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.